Treatment
Fingolimod clinical trials
We’re tracking 7 recruiting studies that include Fingolimod, each written for real people, not researchers, below.
Recruiting studies
- NCT04480853RecruitingPhase 4
Fingolimod start study for adults with relapsing MS
This study checks how safe and effective fingolimod is when adults with relapsing-remitting multiple sclerosis start it for the first time. It may help confirm whether this treatment works well and is tolerated in newly treated patients.
Kaohsiung CityAges 20–100 - NCT05307731RecruitingPhase 4
Fingolimod for adults with type 2 diabetes
This trial studies whether fingolimod can improve diabetes in adults with type 2 diabetes who are not yet on many medications. It will mainly check whether the drug is safe and whether it can help control blood sugar over time.
ShenyangAges 18–70 - NCT06408259RecruitingPhase 3
Comparing ozanimod and fingolimod for children with MS
This study compares two oral medications, ozanimod and fingolimod, to see which one works better and is safer for children and teenagers with relapsing-remitting MS. Both drugs help reduce MS attacks and slow down the disease.
Loma Linda, CaliforniaAges 10–17 - NCT06424067RecruitingPhase 2
Fingolimod for advanced lung cancer
This trial tests if the drug fingolimod can help people with advanced non-small cell or small cell lung cancer that has worsened after at least two previous treatments. Fingolimod is a pill taken daily that may help the immune system fight the cancer.
Charleston, South CarolinaAges 18 years+ - NCT05285878Enrolling by invitationPhase 2
Fingolimod to protect kidney function after kidney transplant
This trial tests whether fingolimod can reduce kidney scarring and preserve kidney function after a new kidney transplant. It focuses on people who are in the early period after transplant who may be at risk for scarring in the kidney.
Houston, TexasAges 18–65 - NCT07220252RecruitingPhase 2/Phase 3
Ublituximab for children with relapsing multiple sclerosis
This trial tests a new drug called ublituximab to see if it can reduce flare-ups in children and teens who have relapsing multiple sclerosis. It aims to understand if the treatment is safe and effective for younger patients.
GdanskAges 10–17 - NCT04676204Enrolling by invitation
How MS treatment “burden” may affect taking medicines
This study looks at whether the amount of MS treatment-related “burden” in the mouth and body affects how well people stick to their disease-modifying therapy. It may help doctors understand which patients are more likely to have trouble following treatment after switching or starting certain MS medicines.
Melbourne, VictoriaAges 18–99
What Fingolimod is being studied for
Conditions with recruiting Fingolimod studies.
Common questions
- Are there clinical trials studying Fingolimod?
- Yes. Clin2 currently lists 7 recruiting studies that include Fingolimod, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Fingolimod trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Fingolimod an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Fingolimod or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.